Oppenheimer analyst Trevor Allred raised the firm’s price target on Dianthus (DNTH) to $62 from $60 and keeps an Outperform rating on the shares. The firm notes Dianthus reported a Q3 net loss of $37M, in line with its $36M estimate. Oppenheimer’s focus is narrowing onto CIDP, as claseprubart’s Phase 3 enrollment looks to be garnering subjects from Sanofi’s (SNY) riliprubart and other therapeutic options. The firm expects CIDP results to garner more investor attention.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics Reports Q3 2025 Financial Results
- Dianthus Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Dianthus reports Q3 EPS (97c), consensus (90c)
- Dianthus Therapeutics Reports Positive Phase 2 Results
- Promising Clinical Data and Strategic Plans Position Dianthus Therapeutics as an Attractive Investment Opportunity